ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Disagree

<< Previous

Bullboard Posts

Next >>

Comment by DavidKingCanadaon Oct 13, 2021 11:01am

154 Views

Post# 34000945

RE:RE:RE:RE:Disagree

Bball, my assumption was based on the Nasdaq Listing Price of $4.00

With the difference in Ratio's you can some what tell what the Marketcap will be.

For example;

At a 25:1 ratio we have 17,000,000 Shares and at Nasdaq Listing of $4.00 we will have a Marketcap of 68,000,000 which is where we are now.